1
|
Laureano AF, Vigato AA, Puzer L, de Araujo DR. Recombinant scFv-Fc Anti-kallikrein 7 Antibody-Loaded Thermosensitive Hydrogels Against Skin Desquamation Disorders. ACS APPLIED BIO MATERIALS 2024; 7:4486-4496. [PMID: 38886921 PMCID: PMC11253099 DOI: 10.1021/acsabm.4c00371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2024] [Revised: 06/01/2024] [Accepted: 06/04/2024] [Indexed: 06/20/2024]
Abstract
Human tissue kallikrein-related peptidase 7 (KLK7) is a serine protease implicated in the physiology of skin desquamation, and its uncontrolled activity can lead to chronic diseases such as psoriasis, atopic dermatitis, and Netherton syndrome. For this reason, kallikrein 7 has been identified as a potential therapeutic target. This work aimed to evaluate Pluronic (PL) hydrogels as topical carriers of four specific scFv-Fc antibodies to inhibit KLK7. The hydrogels comprised PL F127 (30% w/v) alone and a binary F127/P123 (28-2% w/v) system. Each formulation was loaded with 1 μg/mL of each antibody and characterized by physicochemical and pharmaceutical techniques, considering antibody-micelle interactions and hydrogel behavior as smart delivery systems. Results showed that the antibodies were successfully loaded into the PL-based systems, and the sol-gel transition temperature was shifted to high values after the P123 addition. The antibodies released from the gels preserved their rheological properties (G' > G'', 35- to 41-fold) and inhibitory activity against KLK7, even after 24 h. This work presented potential agents targeting KLK7 that may provide strategies for treating skin abnormalities.
Collapse
Affiliation(s)
- Ana Flávia
Santarine Laureano
- Department
of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital & Harvard Medical School, CNY149 13th Street, Charlestown, Boston, Massachusetts 02129, United States
- Centro
de Ciências Naturais e Humanas, Universidade
Federal do ABC, Al. da Universidade, s/n-Anchieta, São
Bernardo do Campo, SP 09606-045, Brazil
| | - Aryane Alves Vigato
- Department
of Biomedical Science (BMV), Faculty of Health and Society, Malmö University, Malmö 20506, Sweden
- Biofilms−Research
Center for Biointerfaces, Malmö University, Malmö 20506, Sweden
| | - Luciano Puzer
- Centro
de Ciências Naturais e Humanas, Universidade
Federal do ABC, Al. da Universidade, s/n-Anchieta, São
Bernardo do Campo, SP 09606-045, Brazil
| | - Daniele Ribeiro de Araujo
- Centro
de Ciências Naturais e Humanas, Universidade
Federal do ABC, Av. dos
Estados, 5001, Bloco A, Torre 3, Santo André, SP 09210-580, Brazil
- Departamento
de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, 862, Vila Clementino, Sao Paulo, SP 04023-062, Brazil
| |
Collapse
|
2
|
Wound Healing from an Actin Cytoskeletal Perspective. Cold Spring Harb Perspect Biol 2022; 14:cshperspect.a041235. [DOI: 10.1101/cshperspect.a041235] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Haidari H, Bright R, Garg S, Vasilev K, Cowin AJ, Kopecki Z. Eradication of Mature Bacterial Biofilms with Concurrent Improvement in Chronic Wound Healing Using Silver Nanoparticle Hydrogel Treatment. Biomedicines 2021; 9:1182. [PMID: 34572368 PMCID: PMC8470956 DOI: 10.3390/biomedicines9091182] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 09/05/2021] [Accepted: 09/05/2021] [Indexed: 12/15/2022] Open
Abstract
Biofilm-associated infections are a major cause of impaired wound healing. Despite the broad spectrum of anti-bacterial benefits provided by silver nanoparticles (AgNPs), these materials still cause controversy due to cytotoxicity and a lack of efficacy against mature biofilms. Herein, highly potent ultrasmall AgNPs were combined with a biocompatible hydrogel with integrated synergistic functionalities to facilitate elimination of clinically relevant mature biofilms in-vivo combined with improved wound healing capacity. The delivery platform showed a superior release mechanism, reflected by high biocompatibility, hemocompatibility, and extended antibacterial efficacy. In vivo studies using the S. aureus wound biofilm model showed that the AgNP hydrogel (200 µg/g) was highly effective in eliminating biofilm infection and promoting wound repair compared to the controls, including silver sulfadiazine (Ag SD). Treatment of infected wounds with the AgNP hydrogel resulted in faster wound closure (46% closure compared to 20% for Ag SD) and accelerated wound re-epithelization (60% for AgNP), as well as improved early collagen deposition. The AgNP hydrogel did not show any toxicity to tissue and/or organs. These findings suggest that the developed AgNP hydrogel has the potential to be a safe wound treatment capable of eliminating infection and providing a safe yet effective strategy for the treatment of infected wounds.
Collapse
Affiliation(s)
- Hanif Haidari
- Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (H.H.); (S.G.)
- Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia;
| | - Richard Bright
- Academic Unit of STEM, University of South Australia, Mawson Lakes, SA 5095, Australia;
| | - Sanjay Garg
- Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (H.H.); (S.G.)
| | - Krasimir Vasilev
- Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia;
- Academic Unit of STEM, University of South Australia, Mawson Lakes, SA 5095, Australia;
| | - Allison J. Cowin
- Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (H.H.); (S.G.)
- Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia;
| | - Zlatko Kopecki
- Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (H.H.); (S.G.)
- Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia;
| |
Collapse
|
4
|
Baylet A, Vyumvuhore R, Laclaverie M, Marchand L, Mainzer C, Bordes S, Closs-Gonthier B, Delpy L. Transcutaneous penetration of a single-chain variable fragment (scFv) compared to a full-size antibody: potential tool for atopic dermatitis (AD) treatment. Allergy Asthma Clin Immunol 2021; 17:73. [PMID: 34281610 PMCID: PMC8290589 DOI: 10.1186/s13223-021-00574-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Accepted: 06/28/2021] [Indexed: 11/10/2022] Open
Abstract
Currently, several biologics are used for the treatment of cutaneous pathologies such as atopic dermatitis (AD), psoriasis or skin cancers. The main administration routes are subcutaneous and intravenous injections. However, little is known about antibody penetration through the skin. The aim was to study the transcutaneous penetration of a reduced-size antibody as a single-chain variable fragment (scFv) compared to a whole antibody (Ab) and to determine its capacity to neutralize an inflammatory cytokine involved in AD such as human interleukin-4 (hIL-4). Transcutaneous penetration was evaluated by ex vivo studies on tape-stripped pig ear skin. ScFv and Ab visualization through the skin was measured by Raman microspectroscopy. In addition, hIL-4 neutralization was studied in vitro using HEK-Blue™ IL-4/IL-13 cells and normal human keratinocytes (NHKs). After 24 h of application, analysis by Raman microspectroscopy showed that scFv penetrated into the upper dermis while Ab remained on the stratum corneum. In addition, the anti-hIL4 scFv showed very efficient and dose-dependent hIL-4 neutralization. Thus, scFv penetrates through to the upper papillary dermis while Ab mostly remains on the surface, the anti-hIL4 scFv also neutralizes its target effectively suggesting its potential use as topical therapy for AD.
Collapse
Affiliation(s)
- Audrey Baylet
- Unité Mixte de Recherche CNRS, 7276-INSERM U1262-Université de Limoges, CBRS, 2 rue du Dr Marcland, 87025, Limoges, France.,Silab R&D Department, Brive, France
| | | | | | | | | | | | | | - Laurent Delpy
- Unité Mixte de Recherche CNRS, 7276-INSERM U1262-Université de Limoges, CBRS, 2 rue du Dr Marcland, 87025, Limoges, France.
| |
Collapse
|
5
|
Haidari H, Bright R, Strudwick XL, Garg S, Vasilev K, Cowin AJ, Kopecki Z. Multifunctional ultrasmall AgNP hydrogel accelerates healing of S. aureus infected wounds. Acta Biomater 2021; 128:420-434. [PMID: 33857695 DOI: 10.1016/j.actbio.2021.04.007] [Citation(s) in RCA: 54] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 04/05/2021] [Accepted: 04/06/2021] [Indexed: 12/12/2022]
Abstract
The increasing emergence of antibiotic resistance coupled with the limited effectiveness of current treatments highlights the need for the development of new treatment modalities. Silver nanoparticles (AgNPs) are a promising alternative with broad-spectrum antibacterial activity. However, the clinical translation of AgNPs have been hampered primarily due to the delivery of unsafe levels of silver ions (Ag+) resulting in cellular toxicity and their susceptibility to aggregation resulting in loss of efficacy. Here, we describe a safe and effective, thermo-responsive AgNP hydrogel that provides antibacterial effects in conjunction with wound promoting properties. Using a murine model of wound infection, we demonstrate that the applied AgNP hydrogel to the wound (12 µg silver) not only provides superior bactericidal activity but also reduces inflammation leading to accelerated wound closure when compared to industry-standard silver sulfadiazine (302 µg silver). The AgNP hydrogel-treatment significantly accelerated wound closure at day 4 post-infection (56 closure) compared to both blank hydrogel or Ag SD (74% and 91% closure respectively) with a concurrent increase in PCNA-positive proliferating cells corresponding with a significant 32% improvement in wound re-epithelization compared to the blank hydrogel. Treatment of infected wounds with AgNP hydrogel also decreased neutrophil infiltration, increased anti-inflammatory Ym-1 positive M2 macrophages, and reduced the number of caspase-1 positive apoptotic cells. Therefore, this novel multifunctional AgNP thermo-responsive hydrogel is potentially a safe and effective treatment at much lower concentration for the treatment of wound infections. STATEMENT OF SIGNIFICANCE: In this study, we describe the development of a multifunctional thermo-responsive hydrogel of ultrasmall silver nanoparticles (AgNPs) for controlled and optimized delivery of silver to infected wounds. The in vivo biological effects of the developed hydrogel showed significant S. aureus elimination from infected mouse wounds compared to a commercial antibacterial formulation. The developed AgNP hydrogel optimally regulates inflammatory responses to promote wound healing as indicated by increased cell proliferation and wound re-epithelization. Additionally, AgNP hydrogel shows significant potential in regulating neutrophil infiltration while increasing levels of anti-inflammatory M2 macrophages and reduces the number of apoptotic cells. Therefore, the multifunctional properties of the developed AgNP thermo-responsive hydrogel offers great clinical potential to control bacterial infections and promote wound healing.
Collapse
|
6
|
Haidari H, Kopecki Z, Sutton AT, Garg S, Cowin AJ, Vasilev K. pH-Responsive "Smart" Hydrogel for Controlled Delivery of Silver Nanoparticles to Infected Wounds. Antibiotics (Basel) 2021; 10:49. [PMID: 33466534 PMCID: PMC7824857 DOI: 10.3390/antibiotics10010049] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 12/31/2020] [Accepted: 12/31/2020] [Indexed: 11/16/2022] Open
Abstract
Persistent wound infections have been a therapeutic challenge for a long time. Current treatment approaches are mostly based on the delivery of antibiotics, but these are not effective for all infections. Here, we report the development of a sensitive pH-responsive hydrogel that can provide controlled, pH-triggered release of silver nanoparticles (AgNPs). This delivery system was designed to sense the environmental pH and trigger the release of AgNPs when the pH changes from acidic to alkaline, as occurs due to the presence of pathogenic bacteria in the wound. Our results show that the prepared hydrogel restricts the release of AgNPs at acidic pH (pH = 4) but substantially amplifies it at alkaline pH (pH = 7.4 and pH = 10). This indicates the potential use of the hydrogel for the on-demand release of Ag+ depending on the environmental pH. In vitro antibacterial studies demonstrated effective elimination of both Gram-negative and positive bacteria. Additionally, the effective antibacterial dose of Ag+ showed no toxicity towards mammalian skin cells. Collectively, this pH-responsive hydrogel presents potential as a promising new material for the treatment of infected wounds.
Collapse
Affiliation(s)
- Hanif Haidari
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (H.H.); (Z.K.); (S.G.); (A.J.C.)
- Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia;
| | - Zlatko Kopecki
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (H.H.); (Z.K.); (S.G.); (A.J.C.)
- Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia;
| | - Adam T. Sutton
- Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia;
| | - Sanjay Garg
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (H.H.); (Z.K.); (S.G.); (A.J.C.)
| | - Allison J. Cowin
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; (H.H.); (Z.K.); (S.G.); (A.J.C.)
- Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia;
| | - Krasimir Vasilev
- Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia;
- Academic Unit of STEM, University of South Australia, Mawson Lakes, SA 5095, Australia
| |
Collapse
|
7
|
Strudwick XL, Cowin AJ. Multifunctional Roles of the Actin-Binding Protein Flightless I in Inflammation, Cancer and Wound Healing. Front Cell Dev Biol 2020; 8:603508. [PMID: 33330501 PMCID: PMC7732498 DOI: 10.3389/fcell.2020.603508] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 10/30/2020] [Indexed: 11/20/2022] Open
Abstract
Flightless I is an actin-binding member of the gelsolin family of actin-remodeling proteins that inhibits actin polymerization but does not possess actin severing ability. Flightless I functions as a regulator of many cellular processes including proliferation, differentiation, apoptosis, and migration all of which are important for many physiological processes including wound repair, cancer progression and inflammation. More than simply facilitating cytoskeletal rearrangements, Flightless I has other important roles in the regulation of gene transcription within the nucleus where it interacts with nuclear hormone receptors to modulate cellular activities. In conjunction with key binding partners Leucine rich repeat in the Flightless I interaction proteins (LRRFIP)1/2, Flightless I acts both synergistically and competitively to regulate a wide range of cellular signaling including interacting with two of the most important inflammatory pathways, the NLRP3 inflammasome and the MyD88-TLR4 pathways. In this review we outline the current knowledge about this important cytoskeletal protein and describe its many functions across a range of health conditions and pathologies. We provide perspectives for future development of Flightless I as a potential target for clinical translation and insights into potential therapeutic approaches to manipulate Flightless I functions.
Collapse
Affiliation(s)
- Xanthe L Strudwick
- Regenerative Medicine, Future Industries Institute, University of South Australia, Mawson Lakes, SA, Australia
| | - Allison J Cowin
- Regenerative Medicine, Future Industries Institute, University of South Australia, Mawson Lakes, SA, Australia
| |
Collapse
|
8
|
Baylet A, Laclaverie M, Marchand L, Bordes S, Closs-Gonthier B, Delpy L. Immunotherapies in cutaneous pathologies: an overview. Drug Discov Today 2020; 26:248-255. [PMID: 33137480 DOI: 10.1016/j.drudis.2020.10.023] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 10/02/2020] [Accepted: 10/26/2020] [Indexed: 12/13/2022]
Abstract
Skin is a vital protective organ, the main role of which is to provide a physical barrier and to prevent the entry of pathogens. Various pathologies, such as atopic dermatitis (AD), psoriasis (PSO), or skin cancers, can affect the skin, and all show a high and increasing prevalence. Many antibodies are currently used in the treatment of these diseases. However, various studies are underway for the development of new biologics directed against specific targets. In this review, we describe current biologics used in skin pathologies as well as antibodies in development. We also discuss various immunotherapy examples that use new delivery technologies, such as microneedle patch, nanoparticles (NPs), liposomes, or gel formulation.
Collapse
Affiliation(s)
- Audrey Baylet
- Unité Mixte de Recherche CNRS 7276 - INSERM U1262 - Université de Limoges, CBRS, 2 rue du Dr Marcland, 87025 Limoges, France; Silab R&D Department, Brive, France
| | | | | | | | | | - Laurent Delpy
- Unité Mixte de Recherche CNRS 7276 - INSERM U1262 - Université de Limoges, CBRS, 2 rue du Dr Marcland, 87025 Limoges, France.
| |
Collapse
|
9
|
Haidari H, Kopecki Z, Bright R, Cowin AJ, Garg S, Goswami N, Vasilev K. Ultrasmall AgNP-Impregnated Biocompatible Hydrogel with Highly Effective Biofilm Elimination Properties. ACS APPLIED MATERIALS & INTERFACES 2020; 12:41011-41025. [PMID: 32840353 DOI: 10.1021/acsami.0c09414] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Ultrasmall silver nanoparticles (AgNPs; size < 3 nm) have attracted a great deal of interest as an alternative to commercially available antibiotics due to their ability to eliminate a wide range of microbial pathogens. However, most of these ultrasmall AgNPs are highly reactive and unstable, as well as susceptible to fast oxidation. Therefore, both the stability and toxicity remain major shortcomings for their clinical application and uptake. To circumvent these problems, we present a novel strategy to impregnate ultrasmall AgNPs into a biocompatible thermosensitive hydrogel that enables controlled release of silver alongside long-term storage stability and highly potent antibacterial activity. The advantage of this strategy lies in the combination of a homogenous dispersion of AgNPs in a hydrogel network, which serves as a sustained-release reservoir, and the unique feature of ultrasmall AgNP size, which provides an improved biofilm eradication capacity. The superior biofilm dispersion properties of the AgNP hydrogel is demonstrated in both single-species and multispecies biofilms, eradicating ∼80% of established biofilms compared to untreated controls. Notably, the effective antibacterial concentration of the formulation shows minimal toxicity to human fibroblasts and keratinocytes. These findings present a promising novel strategy for the development of AgNP hydrogels as an efficient antibacterial platform to combat resistant bacterial biofilms associated with wound infections.
Collapse
Affiliation(s)
| | | | | | | | | | - Nirmal Goswami
- Materials Chemistry Department, CSIR-Institute of Minerals and Materials Technology, Acharya Vihar, Bhubaneswar 751013, India
| | | |
Collapse
|
10
|
Kuang Y, Zorzi V, Buratto D, Ziraldo G, Mazzarda F, Peres C, Nardin C, Salvatore AM, Chiani F, Scavizzi F, Raspa M, Qiang M, Chu Y, Shi X, Li Y, Liu L, Shi Y, Zonta F, Yang G, Lerner RA, Mammano F. A potent antagonist antibody targeting connexin hemichannels alleviates Clouston syndrome symptoms in mutant mice. EBioMedicine 2020; 57:102825. [PMID: 32553574 PMCID: PMC7378960 DOI: 10.1016/j.ebiom.2020.102825] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 05/22/2020] [Accepted: 05/22/2020] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Numerous currently incurable human diseases have been causally linked to mutations in connexin (Cx) genes. In several instances, pathological mutations generate abnormally active Cx hemichannels, referred to also as "leaky" hemichannels. The goal of this study was to assay the in vivo efficacy of a potent antagonist antibody targeting Cx hemichannels. METHODS We employed the antibody to treat Cx30A88V/A88V adult mutant mice, the only available animal model of Clouston syndrome, a rare orphan disease caused by Cx30 p.A88V leaky hemichannels. To gain mechanistic insight into antibody action, we also performed patch clamp recordings, Ca2+ imaging and ATP release assay in vitro. FINDINGS Two weeks of antibody treatment sufficed to repress cell hyperproliferation in skin and reduce hypertrophic sebaceous glands (SGs) to wild type (wt) levels. These effects were obtained whether mutant mice were treated topically, by application of an antibody cream formulation, or systemically, by intraperitoneal antibody injection. Experiments with mouse primary keratinocytes and HaCaT cells revealed the antibody blocked Ca2+ influx and diminished ATP release through leaky Cx30 p.A88V hemichannels. INTERPRETATION Our results show anti-Cx antibody treatment was effective in vivo and sufficient to counteract the effects of pathological connexin expression in Cx30A88V/A88V mice. In vitro experiments suggest antibodies gained control over leaky hemichannels and contributed to restoring epidermal homeostasis. Therefore, regulating cell physiology by antibodies targeting the extracellular domain of Cxs may enforce an entirely new therapeutic strategy. These findings support the further development of antibodies as drugs to address unmet medical needs for Cx-related diseases. FUND: Fondazione Telethon, GGP19148; University of Padova, SID/BIRD187130; Consiglio Nazionale delle Ricerche, DSB.AD008.370.003\TERABIO-IBCN; National Science Foundation of China, 31770776; Science and Technology Commission of Shanghai Municipality, 16DZ1910200.
Collapse
Affiliation(s)
- Yuanyuan Kuang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, ShanghaiTech University, 201210 Shanghai, China; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 200031 Shanghai, China; University of Chinese Academy of Sciences, 100049 Beijing, China
| | - Veronica Zorzi
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Institute of Otorhinolaryngology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Damiano Buratto
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Gaia Ziraldo
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Institute of Otorhinolaryngology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Flavia Mazzarda
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Department of Science, Roma3 University, 00146 Rome, Italy
| | - Chiara Peres
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Department of Physics and Astronomy "G. Galilei", University of Padova, 35131 Padova, Italy
| | - Chiara Nardin
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Department of Physics and Astronomy "G. Galilei", University of Padova, 35131 Padova, Italy
| | | | - Francesco Chiani
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy
| | | | - Marcello Raspa
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy
| | - Min Qiang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Youjun Chu
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Xiaojie Shi
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Yu Li
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, ShanghaiTech University, 201210 Shanghai, China; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 200031 Shanghai, China; University of Chinese Academy of Sciences, 100049 Beijing, China
| | - Lili Liu
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Yaru Shi
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Francesco Zonta
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Guang Yang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
| | - Richard A Lerner
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; Department of Chemistry, Scripps Research Institute, La Jolla, CA 92037, U.S.A..
| | - Fabio Mammano
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Department of Physics and Astronomy "G. Galilei", University of Padova, 35131 Padova, Italy.
| |
Collapse
|
11
|
A Multifunctional Wearable Device with a Graphene/Silver Nanowire Nanocomposite for Highly Sensitive Strain Sensing and Drug Delivery. C — JOURNAL OF CARBON RESEARCH 2019. [DOI: 10.3390/c5020017] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Advances in wearable, highly sensitive and multifunctional strain sensors open up new opportunities for the development of wearable human interface devices for various applications such as health monitoring, smart robotics and wearable therapy. Herein, we present a simple and cost-effective method to fabricate a multifunctional strain sensor consisting of a skin-mountable dry adhesive substrate, a robust sensing component and a transdermal drug delivery system. The sensor has high piezoresisitivity to monitor real-time signals from finger bending to ulnar pulse. A transdermal drug delivery system consisting of polylactic-co-glycolic acid nanoparticles and a chitosan matrix is integrated into the sensor and is able to release the nanoparticles into the stratum corneum at a depth of ~60 µm. Our approach to the design of multifunctional strain sensors will lead to the development of cost-effective and well-integrated multifunctional wearable devices.
Collapse
|
12
|
Schwartz J, Moreno E, Calvo A, Blanco L, Fernández-Rubio C, Sanmartín C, Nguewa P, Irache JM, Larrea E, Espuelas S. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions. J Dermatol Sci 2018; 92:78-88. [PMID: 30037731 DOI: 10.1016/j.jdermsci.2018.07.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2018] [Revised: 07/05/2018] [Accepted: 07/12/2018] [Indexed: 12/21/2022]
Abstract
BACKGROUND Cutaneous leishmaniasis (CL) skin lesions are the result of a deregulated immune response, which is unable to eliminate Leishmania parasites. The control of both, parasites and host immune response, is critical to prevent tissue destruction. The skin ulceration has been correlated with high TNF-α level. OBJECTIVE Because human anti-TNF-α antibodies (Ab) have been successfully assayed in several mice inflammatory diseases, we hypothesized that their anti-inflammatory effect could optimize the healing of CL lesions achieved after topical application of paromomycin (PM), the current chemotherapy against CL. METHODS AND RESULTS We first compared the in vitro efficacy of PM and Ab alone and the drug given in combination with Ab to assess if the Ab could interfere with PM leishmanicidal activity in L. major-infected bone marrow-derived macrophages. The combination therapy had similar antileishmanial activity to the drug alone and showed no influence on NO production, which allows macrophage-mediated parasite killing. Next, we demonstrated in an in vivo model of Imiquimod®-induced inflammation that topical Ab and PM inhibit the infiltration of inflammatory cells in the skin. In the efficacy studies in L. major-infected BALB/c mice, PM combined with Ab led to a sharp infection reduction and showed a stronger anti-inflammatory activity than PM alone. This was confirmed by the down-regulation of TNF-α, IL-1β, iNOS, IL-17, and CCL3 as well as by a decrease of the neutrophilic infiltrate during infection upon treatment with the Ab. CONCLUSIONS In terms of parasite elimination and inflammation reduction, topical application of Ab in combination with PM was more effective than the drug alone.
Collapse
Affiliation(s)
- Juana Schwartz
- Tropical Health Institute, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Pharmacy and Pharmaceutical Technology Department, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Navarra Institute for Health Research, IdisNA, Spain
| | - Esther Moreno
- Tropical Health Institute, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Pharmacy and Pharmaceutical Technology Department, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Navarra Institute for Health Research, IdisNA, Spain; Organic and Pharmaceutical Chemistry Department, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain
| | - Alba Calvo
- Tropical Health Institute, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Pharmacy and Pharmaceutical Technology Department, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Navarra Institute for Health Research, IdisNA, Spain
| | - Laura Blanco
- Tropical Health Institute, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Pharmacy and Pharmaceutical Technology Department, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Navarra Institute for Health Research, IdisNA, Spain
| | - Celia Fernández-Rubio
- Tropical Health Institute, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Navarra Institute for Health Research, IdisNA, Spain; Microbiology and Parasitology Department, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain
| | - Carmen Sanmartín
- Tropical Health Institute, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Navarra Institute for Health Research, IdisNA, Spain; Organic and Pharmaceutical Chemistry Department, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain
| | - Paul Nguewa
- Tropical Health Institute, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Navarra Institute for Health Research, IdisNA, Spain; Microbiology and Parasitology Department, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain
| | - Juan M Irache
- Pharmacy and Pharmaceutical Technology Department, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Navarra Institute for Health Research, IdisNA, Spain
| | - Esther Larrea
- Tropical Health Institute, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Navarra Institute for Health Research, IdisNA, Spain
| | - Socorro Espuelas
- Tropical Health Institute, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Pharmacy and Pharmaceutical Technology Department, University of Navarra, Irunlarrea 1, E-31008, Pamplona, Spain; Navarra Institute for Health Research, IdisNA, Spain.
| |
Collapse
|